, Volume 78, Issue 17, pp 1783–1790 | Cite as

A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension

  • Arrigo F. G. Cicero
  • Masanari Kuwabara
  • Claudio BorghiEmail author
Review Article


β-Adrenergic receptor blockers (β-blockers) are well-known useful and cost-effective drugs for managing hypertensive patients with coronary heart disease, stroke, and heart failure. However, it is often difficult to use β-blockers for patients with asthma or chronic obstructive pulmonary disease (COPD). Moreover, most β-blockers negatively influence glucose or lipid metabolism. Nebivolol is a third-generation lipophilic β-1 receptor-selective blocker with nitric oxide-mediated vasodilatory effects, metabolically neutral and usually well tolerated by patients with asthma or COPD. Nebivolol has significant effects of reduction in central blood pressure and improvements in endothelial dysfunction and arterial stiffness. To summarize the merits and demerits of nebivolol in different clinical situations, we conducted a review using the word ‘nebivolol’ on Pubmed and Embase, limiting the search to hypertension, clinical trials, and meta-analyses. This review summarizes the clinical studies on nebivolol itself and on the combination of nebivolol with other antihypertensive drugs, such as hydrochlorothiazide, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, and amlodipine. Most studies showed the safety and well-tolerated profile of nebivolol and the combination of nebivolol with other antihypertensive drugs, which suggests that new fixed combinations of nebivolol with other antihypertensive drugs would be useful for patients who are unable to tolerate traditional β-blockers.


Compliance with Ethical Standards


No funding was received for the preparation of this manuscript.

Conflict of interest

CB and AFGC have received grants and are part of consulting boards of Menarini Pharmaceutical Industries SpA (Firenze, Italy). MK declares that they haveno potential conflicts of interest that might be relevant to the contents of this manuscript.


  1. 1.
    Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003.Google Scholar
  2. 2.
    Peyracchia M, Errigo D, Raposeiras Rubin S, Conrotto F, DiNicolantonio JJ, Omedè P, Rettegno S, Iannaccone M, Moretti C, D’Amico M, Gaita F, D’Ascenzo F. Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results. J Cardiovasc Med. 2018;19(7):337–43.CrossRefGoogle Scholar
  3. 3.
    Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Böhm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson Å, Kjekshus J, Cleland JGF; Beta-Blockers in Heart Failure Collaborative Group. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol. 2017;69(24):2885–2896.Google Scholar
  4. 4.
    Ma G, Fang Q, Wang F. The effect of beta-blockers on mortality in patients with heart failure and atrial fibrillation: A meta-analysis of observational cohort and randomized controlled studies. Cardiol J. 2018. (Epub ahead of print).
  5. 5.
    Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D, Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26–35.Google Scholar
  6. 6.
    Ram CV. Beta-blockers in hypertension. Am J Cardiol. 2010;106:1819–25.CrossRefGoogle Scholar
  7. 7.
    Wang Y, Dong X. Nebivolol ameliorates asymmetric dimethylarginine-induced vascular response in rat aorta via β3 adrenoceptor-mediated mechanism. Clin Exp Hypertens. 2016;38(2):252–9.CrossRefGoogle Scholar
  8. 8.
    Gupta S, Wright HM. Nebivolol: a highly selective β 1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther. 2008;26:189–202.CrossRefGoogle Scholar
  9. 9.
    Ignarro LJ. Different pharmacological properties of two enantiomers in a unique β-blocker, nebivolol. Cardiovasc Ther. 2008;26:115–34.CrossRefGoogle Scholar
  10. 10.
    McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999;57(4):633–51.CrossRefGoogle Scholar
  11. 11.
    Borghi C, Acelajado MC, Gupta Y, Jain S. Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients. J Hum Hypertens. 2017;31(10):605–10.CrossRefGoogle Scholar
  12. 12.
    Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther. 2009;31(3):447–62.CrossRefGoogle Scholar
  13. 13.
    Shamekhi Amiri F. Recent advances in the treatment of renal diseases with nebivolol: a literature review. Nephrol Ther. 2016;12(3):140–8.CrossRefGoogle Scholar
  14. 14.
    Sharp RP, Gales BJ. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction. Ther Adv Urol. 2017;9(2):59–63. Scholar
  15. 15.
    Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs. 2015;75(12):1349–71.CrossRefGoogle Scholar
  16. 16.
    Ozaydin M, Yucel H, Kocyigit S, Adali MK, Aksoy F, Kahraman F, Uysal BA, Erdogan D, Varol E, Dogan A. Nebivolol versus carvedilol or metoprolol in patients presenting with acute myocardial infarction complicated by left ventricular dysfunction. Med Princ Pract. 2016;25(4):316–22.CrossRefGoogle Scholar
  17. 17.
    Kaltwasser MT. Economic evaluation of nebivolol in the treatment of hypertension. Am J Cardiovasc Drugs. 2005;5(5):319–24.CrossRefGoogle Scholar
  18. 18.
    Sander GE, Giles TD. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension. Expert Opin Pharmacother. 2015;16(5):763–70.CrossRefGoogle Scholar
  19. 19.
    Marketou M, Gupta Y, Jain S, Vardas P. Differential metabolic effects of beta-blockers: an updated systematic review of nebivolol. Curr Hypertens Rep. 2017;19(3):22.CrossRefGoogle Scholar
  20. 20.
    Fares H, Lavie CJ, Ventura HO. Vasodilating versus first-generation beta-blockers for cardiovascular protection. Postgrad Med. 2012;124:7–15.CrossRefGoogle Scholar
  21. 21.
    Hocht C, Bertera FM, Del Mauro JS, Santander Plantamura Y, Taira CA, Polizio AH. What is the real efficacy of beta-blockers for the treatment of essential hypertension? Curr Pharm Des. 2017;23:4658–77.CrossRefGoogle Scholar
  22. 22.
    Cruickshank JM. Beta-blockers and heart failure. Indian Heart J. 2010;62:101–10.PubMedGoogle Scholar
  23. 23.
    Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, et al. Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis. Curr Med Res Opin. 2012;28:591–9.CrossRefGoogle Scholar
  24. 24.
    BYSTOLIC (nebivolol) tablets homepage. Accessed 12 Oct 2018.
  25. 25.
    Roush GC, Sica DA. Diuretics for hypertension: a review and update. Am J Hypertens. 2016;29(10):1130–7.CrossRefGoogle Scholar
  26. 26.
    Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, et al. Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension. Curr Med Res Opin. 2014;30(4):637–43.CrossRefGoogle Scholar
  27. 27.
    Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens. 2011;29(7):1448–56.Google Scholar
  28. 28.
    Lacourciere Y, Lefebvre J, Poirier L, Archambault F, Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens. 1994;7(2):137–45.Google Scholar
  29. 29.
    Lacourciere Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens. 1994;8(4):283–8.PubMedGoogle Scholar
  30. 30.
    Khan BV, Rahman ST, Haque T, Merchant N, Bhaheetharan S, Harris J 3rd, Umar K, Wahi J, Ferdinand KC. Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study. J Cardiovasc Pharmacol Ther. 2012;17(3):291–7.CrossRefGoogle Scholar
  31. 31.
    Vitale C, Marazzi G, Iellamo F, Spoletini I, Dall’Armi V, Fini M, Volterrani M. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol. 2012;155(2):279–84.CrossRefGoogle Scholar
  32. 32.
    Grassi G, Seravalle G, Brambilla G, Dell’Oro R, Trevano FQ, Fici F, van Bortel L, Mancia G. Multicenter randomized double-blind comparison of nebivolol plus HCTZ and irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients: results of the NEHIS study. Adv Ther. 2017;33(12):2173–87.CrossRefGoogle Scholar
  33. 33.
    Brugts JJ, Bertrand M, Remme W, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML, Boersma E. The treatment effect of an ACE-inhibitor based regimen with perindopril in relation to beta-blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovasc Drugs Ther. 2017;31(4):391–400.CrossRefGoogle Scholar
  34. 34.
    Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. Drugs. 2009;69(17):2393–414.CrossRefGoogle Scholar
  35. 35.
    Chen CL, Desai-Krieger D, Ortiz S, Kerolous M, Wright HM, Ghahramani P. A single-center, open-label, 3-way crossover trial to determine the pharmacokinetic and pharmacodynamic interaction between nebivolol and valsartan in healthy volunteers at steady state. Am J Ther. 2015;22(5):e130–40.CrossRefGoogle Scholar
  36. 36.
    Izzo J, Saleem O, Khan S, Osmond P. 7b.05: Differential effects nebivolol and valsartan alone and in combination on 24-hour ambulatory rate-pressure product, stroke load, and blood pressure-heart rate variability. J Hypertens. 2015;33(Suppl 1):e93.Google Scholar
  37. 37.
    Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M; NAC-MD-01 Study Investigators.Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383(9932):1889–98.Google Scholar
  38. 38.
    Giles TD, Bakris G, Oparil S, Weber MA, Li H, Mallick M, Mallick M, Bharucha DB, Chen C, Ferguson WG; NAC-MD-01 Substudy Investigators. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015;9(11):845–54.Google Scholar
  39. 39.
    Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM. Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data. J Hypertens. 2017;35(9):1758–67.CrossRefGoogle Scholar
  40. 40.
    Ishak J, Rael M, Punzi H, Gradman A, Anderson LM, Patel M, Ali S, Ferguson W, Neutel J. Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension. J Clin Hypertens. 2018;20(1):143–9.CrossRefGoogle Scholar
  41. 41.
    Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs. 2007;67(9):1309–27.CrossRefGoogle Scholar
  42. 42.
    van Zwieten PA. The pharmacological properties of lipophilic calcium antagonists. Blood Press Suppl. 1998;2:5–9.CrossRefGoogle Scholar
  43. 43.
    Punzi HA. Combination therapy with nebivolol/amlodipine is superior to metoprolol/amlodipine in the control of 24-hour ABPM. J Am Soc Hypertens. 2015; 9(4S) 2015. P-16.Google Scholar
  44. 44.
    Pecherina TB, Vedernikova AG, Evdokimov DO, Klimenkova AV, Barbarash OL. Postregistration study of comparative assessment efficacy of the use of fixed combination of nebivolol and amlodipine for the treatment of patients with moderate and high degree of arterial hypertension. Kardiologiia. 2014;54(6):21–8.CrossRefGoogle Scholar
  45. 45.
    Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387(10022):957–967.Google Scholar
  46. 46.
    Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018;36(8):1637–47.CrossRefGoogle Scholar
  47. 47.
    Du LP, Cheng ZW, Zhang YX, Li Y, Mei D. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens. 2018;20(5):902–7.CrossRefGoogle Scholar
  48. 48.
    Stephan D, Gaertner S, Cordeanu EM. A critical appraisal of the guidelines from France, the UK, Europe and the USA for the management of hypertension in adults. Arch Cardiovasc Dis. 2015;108:453–9.CrossRefGoogle Scholar
  49. 49.
    Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs—overview and meta-analyses. J Hypertens 2015;33:1321–1341.Google Scholar
  50. 50.
    Basile J, Egan B, Punzi H, Ali S, Li Q, Patel M, Neutel J. Risk of hospitalization for cardiovascular events with β-blockers in hypertensive patients: a retrospective cohort study. Cardiol Ther. 2018. (Epub ahead of print).

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Arrigo F. G. Cicero
    • 1
  • Masanari Kuwabara
    • 2
  • Claudio Borghi
    • 1
    Email author
  1. 1.Medical and Surgical Sciences Department, S. Orsola-Malpighi University HospitalUniversity of BolognaBolognaItaly
  2. 2.Department of CardiologyToranomon HospitalTokyoJapan

Personalised recommendations